agilon health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Agilon Health said it exceeded 3rd quarter 2026 guidance across key financial metrics.
- 3rd quarter revenue was approximately $1.5 billion, up 6% from $1.4 billion in the 3rd quarter of 2025.
- Medicare Advantage membership was 454,000 at the end of the 3rd quarter, compared with 437,000 at the end of the 2nd quarter 2026 and 503,000 in the 3rd quarter of 2025; approximately 39,000 members were in care coordination fee arrangements.
- 3rd quarter ACO membership was 112,000, compared with 112,000 in the 2nd quarter of 2026 and 115,000 in the 3rd quarter of 2025.
- The medical services expense ratio was 88.5%, compared with 104% in the 3rd quarter of 2025, driven by higher medical services revenue and lower medical services expense.
- The first-half 2026 cost trend is now estimated in the low 6% range, while the recorded 3rd quarter cost trend was in the low 7% range.
- Adjusted EBITDA was $64 million, compared with negative $91 million in the 3rd quarter of 2025, and exceeded the midpoint of 3rd quarter guidance by approximately $64 million.
- ACO REACH adjusted EBITDA was $11 million, compared with previous guidance of approximately breakeven.
- Agilon ended the quarter with $312 million in cash and marketable securities and $74 million of off-balance sheet cash held by its ACO entities.
- In measurement year 2025, agilon increased gap closure by 3% versus prior year and achieved a 4.2-star performance for quality measures used by its contracted health plans; the company expects 75% of members to be in 4+ STAR plans for payment year 2028.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I will now hand the conference over to Evan Smith, Senior Vice President, Investor Relations. Evan, please go ahead. Thank you, operator.
Good afternoon and welcome to the call. With me are our CEO, Tim O'Rourke, and our CFO, Jeff Schwaneke. Following our prepared remarks, we will conduct a Q&A session. Before we begin, I would like to remind you that our remarks and responses to questions may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings, including the factors discussed under risk factors in our annual report, Form 10-K, for fiscal year ended December 31, 2025, and subsequent filings. Please note that we assume no obligation to update any forward-looking statements. Additionally, certain financial measures we will discuss in this call are non-GAAP financial measures. Non-GAAP measures are supplemental and not a substitute for GAAP measures.
However, we believe that providing these non-GAAP measures helps investors gain a better and more complete understanding of our financial results and are consistent with how management views our financial results. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is available in the earnings press release and Form 8-K filed with the SEC today. Before I turn the call over to Tim, I wanted to highlight that we will be hosting a virtual investor event on November 17 at 2:00 P.M. Eastern Time titled "Driving Performance at Scale: The agilon Framework," which will be a deep dive into how agilon's technology-enabled clinical and quality programs are advancing patient outcomes and supporting sustainable performance. To register, you can go to agilon's investor relations site under events at investors.agilonhealth.com. With that, let me turn the call over to Tim.
Good afternoon, everyone, and thank you for joining us today. I am pleased to report that agilon exceeded our third quarter guidance across key financial metrics. Based on our performance through the third quarter and our outlook for the remainder of the year, we are increasing our full year 2026 guidance. Jeff will discuss both our financial results and outlook in greater detail. This quarter's performance reflects the continued progress we are making against the operational priorities we established at the beginning of the year. As I highlighted last quarter, we have remained focused on the fundamentals of our business, improving performance at the physician and market level, reducing unnecessary variability, and delivering measurable clinical and quality outcomes. Six months in, I continue to believe agilon sits at the center of where value-based care is going, improving clinical outcomes and quality for patients, and reducing unnecessary medical costs.
The passion and caring of our PCP partners reinforces our mission at agilon health, and it's our absolute responsibility to support these physicians in their work across all of our communities. As we move forward, we will continue to invest in and advance initiatives to further strengthen our platform to support them in their care of patients. We remain confident that our proximity and understanding of our patient populations places agilon health and our PCP partners in what we believe is the best position to have a meaningful impact on daily lives. Realizing the full value of this position depends on our ability to translate proximity into actionable insight, and that is where our investments in data and technology are making a meaningful difference. Our enhanced data capabilities are helping our teams and physician partners identify high-risk patients and gaps in care earlier.
This enables timelier diagnosis and intervention, more effective care coordination, and better management of chronic conditions. Importantly, this is not a series of short-term initiatives. We are building repeatable operating capabilities that can be deployed consistently across our network. We believe this combination of local physician relationships with proximity to the member, actionable data, and operating discipline positions our model to become more resilient and scalable over time. We continue to advance our evidence-based clinical pathways, including our programs for CHF, lung health, and dementia. We are working hand-in-hand with our physician partners, supporting them with additional tools to identify disease earlier and coordinate care more effectively. This end-to-end approach is applied to each high-risk condition we address within our population.
As we have previously stated, heart failure has emerged as a strong proof point for agilon health's technology-enabled clinical pathway framework, using earlier diagnosis and stronger treatment to improve patients' quality of life while reducing avoidable hospital utilization and medical expense. I want to share one particular patient story with you, which I believe demonstrates the effectiveness of this end-to-end clinical pathway. A 72-year-old patient with hypertension and diabetes had quietly accepted leg swelling and shortness of breath as normal aging and never reported them as symptoms. Through agilon health's technology foundation, the patient was identified as a candidate for a risk-based echocardiogram screening and was proactively scheduled. That screening identified significant structural heart disease, which had previously gone undiagnosed.
Following the results, the physician had a structured conversation with the patient to further assess the patient's daily symptoms, which, in combination with echo findings, revealed that the patient was experiencing symptomatic heart failure. The appropriate treatment began promptly with medications optimized in line with guideline-directed medical therapy, or GDMT. At the one-month follow-up, the patient said the swelling and breathlessness had resolved, and they had felt better than they had in years. This individual's experience demonstrates how agilon health's technology-enabled screening, physician training, and a trusted PCP relationship can turn an overlooked condition into earlier treatment, a meaningful improvement in daily life, and reduce unnecessary medical utilization. While CHF pathways have been successful, there are still more opportunities to provide improved care and drive enhanced outcomes. We are continuing to roll out virtual pharmacy across our markets to drive greater adherence to GDMT and further improve performance.
Similarly, we are executing a consistent framework for our other end-to-end pathways, including dementia. We are also investing in technology and AI-enabled capabilities that can surface relevant information at the point of care, reduce administrative work, engage other patients, and help physicians focus their time on those with the greatest needs. We view these tools as force multipliers for primary care. Their value comes from combining technology with the judgment and experience of a trusted physician who understands the patient, the family, and the local community. It is integrating diverse structured and unstructured patient data to drive actionable insights embedded in both agilon and the PCP workflows to support improved patient care and outcomes, and reduce unnecessary medical costs. Through increased performance visibility across markets and payers, we believe we can uncover patterns earlier, reduce performance variability, and more effectively leverage best practices nationwide.
Quality remains central to our model and to the value we create for patients, physicians, and health plan partners. Our physician partners show up every day to deliver better, more coordinated care for their patients. This is supported by timely data and insights, accurate attribution, and proactive collaboration, so care gaps are addressed before they become health issues. That commitment shows up in outcomes. Outcomes result in better management of chronic diseases such as hypertension, cardiovascular disease, and diabetes, more cancer screenings, stronger medication adherence, and more consistent preventative care. To us, these are not metrics, but instead are real people getting healthier. agilon's STARS performance is a result of a highly integrated quality operating model that combines data infrastructure, physician engagement, and payer alignment each and every day.
Following the publication of the measurement year 2025 quality cut points on a consolidated basis, agilon increased gap closure by 3% versus prior year, and consistent with prior year, achieved a 4.2-star performance for quality measures used by our contracted health plans. Based on healthcare plans' overall performance, in measurement year 2025, nationally, we expect 75% of our members to be in four-plus-star plans for payment year 2028, compared with 71% nationally and 77% in payment year 2027. We achieved five-star performance in measures for cardiovascular disease, hypertension, and cancer screenings, as well as four-star performance in measures for diabetes management, all of which reflect the impact of our work in preventative care, chronic disease management, and medication adherence. Looking beyond the quarter, we are encouraged by the continued development of our ACO business and the opportunities we see for 2027 beyond.
We are seeing positive traction and strong interest from both existing and prospective physician partners. Based on the opportunities we've recently announced, we expect ACO membership to grow approximately 40%-50% in 2027, with the majority of that growth expected to come through the Medicare Shared Savings Program, or MSSP, and we'll enter 2027 with a balance between the two models. During the quarter, we announced three relationship expansions for nearly 50,000 MSSP members. In each case, the physician partner already held full-risk Medicare Advantage contracts with agilon, so they know our processes well and have seen firsthand how our model, supported by our clinical and quality programs, can help improve care delivery and positively impact medical outcomes for patients. Through these expansions, we are extending our value-based care approach to traditional Medicare beneficiaries in addition to their previously contracted Medicare Advantage patients.
We believe these expansions are significant to our business for a couple of reasons. First, it demonstrates the embedded growth opportunity and trust we build with our partners over time. As partners experience the benefits of the model, we can further deepen our relationships by extending a consistent care approach across a broader portion of their Medicare populations, improving support and outcomes for patients with the greatest needs. Second, it demonstrates the scalability and flexibility of the agilon platform. We can bring our clinical programs, quality capabilities, technology-enabled workflows, and care management resources to more physicians and patients across multiple value-based care models within the same organization. Our confidence in the opportunity ahead is grounded in demonstrated performance through the ACO business.
As a reminder, in performance year 2024, our eight ACOs generated $229 million in gross savings and achieved an average quality score of 96%, with four earning perfect quality scores and five recognized as high performers. These results, combined with our strong platform capabilities and continued interest, reinforce our belief that the ACO business will remain a strong contributor to agilon's performance in 2027 and beyond. As we enter 2027, we expect both ACO care models may create additional opportunities for agilon and our physician partners. We are taking a measured approach to that growth, prioritizing partnerships where we see strong alignment, a clear path to improved patient outcomes, and the ability to generate sustainable performance over time. We will provide additional detail regarding expected total ACO membership and Adjusted EBITDA contribution when we issue our full-year 2027 guidance in February.
Taken together, the progress this quarter reinforces our confidence in agilon's direction. We believe our operational discipline is strengthening, our clinical programs are becoming more systematic, our physician partnerships are deepening, and our ACO capabilities are enabling us to extend the reach of our model to additional Medicare patients. We still have work ahead of us and remain focused on a few key areas. First, strengthening operational execution across the organization by reducing performance variability, ensuring that our strongest operating practices are consistently adopted across the network, and enhancing our care delivery through the continuation of our clinical and quality programs. Second, disciplined payer contracting. We are in the midst of our 2027 contracting, which will address approximately 50% of our book of business, and we remain focused on reducing risks outside our control while securing economics supportive of the value we provide our physician and payer partners.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
